Starpharma making progress with clinical trials
06 June, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has dosed the first group of patients for a phase I trial of DEP docetaxel in solid tumours and commenced final preparations for a phase III trial of VivaGel for the prevention of BV recurrence.
New guidance for ASX-listed companies
05 June, 2014Two new guidance documents are now available to support ASX-listed companies. The third edition of the ASX's Corporate Governance Principles and Recommendations (CGPR) comes into effect on 1 July after a recent review, and ASIC has released guidance to ASX-listed entities on analyst and investor briefings.
ResMed wins import ban against Taiwan's APEX
05 June, 2014 by Dylan Bushell-EmblingAn ITC judge has ruled that two products from Taiwanese manufacturer APEX still infringe on ResMed (ASX:RMD) patents and cannot be imported or sold in the US.
AusMedtech responds to the TGA's review of the low value turnover exemption scheme
03 June, 2014AusMedtech has told the TGA's review that it is concerned that only a very low number of small businesses are taking advantage of the low value turnover exemption (LVT) scheme, despite the eligibility of their products.
Cochlear to launch new implant in EU in June
02 June, 2014 by Dylan Bushell-EmblingCochlear (ASX:COH) will this month launch the first in its Nucleus Profile line of implants - the successor to its Cl500 series - in Europe.
Benitec treats first patient in HCV trial
02 June, 2014 by Dylan Bushell-EmblingBenitec Biopharma (ASX:BLT) has commenced a phase I/IIa trial of ddRNAi-based therapeutic TT-034, marking the first time the treatment candidate has been used in humans.
Mesoblast accelerates Singapore manufacturing plans
30 May, 2014 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has secured economic incentives in Singapore, as part of efforts to prepare for commercial manufacturing of Prochymal, an allogenic stem cell product awaiting approval in GVHD.
Orthocell launches $8m IPO
30 May, 2014 by Dylan Bushell-EmblingWA's Orthocell has commenced an $8m IPO, as it seeks to raise funds to expand the reach of its two TGA-approved regenerative medicine products and complete development of a third.
Joint position to grow Australia's biopharmaceutical industry
29 May, 2014AusBiotech and Medicines Australia have provided a joint statement to the Minister for Industry, the Hon Ian Macfarlane, proposing steps that the federal government could take to build a stronger biopharmaceutical industry in Australia.
Minomic to seek CE Mark for prostate cancer test
28 May, 2014 by Dylan Bushell-EmblingMinomic International announced that it aims to complete the process of applying for a CE Mark for prostate cancer diagnostics test MiSat ELISA by the fourth quarter.
AusBiotech submission re: tax impediments for small business
27 May, 2014AusBiotech has made a submission to the Board of Taxation, which is conducting a review to identify features in the tax system that are hindering or preventing small businesses from reaching their commercial goals.
ATP Innovations named incubator of the year
27 May, 2014 by Dylan Bushell-EmblingSydney life science and ICT business incubator ATP Innovations has won the Incubator of the Year Award at the NBIA's 2014 International Conference.
FDA knocks back QRxPharma's third Moxduo NDA
26 May, 2014 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) has, as expected, received a third Complete Response Letter from the US FDA covering a New Drug Application for pain drug Moxduo.
Nasal devices improve breathing
23 May, 2014 by Susan WilliamsonPositive results for Rhinomed’s sport and respiratory technology, Turbine, will be followed later this year with the release of its first products targeting snoring and sleep quality.
ResMed refines APAP therapy for women
23 May, 2014 by Dylan Bushell-EmblingResMed (ASX:RMD) has presented research into a new algorithm for providing APAP therapy that has been customised to reflect the distinct symptoms of female sleep apnoea patients.
